Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Zenith Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,825,747

95 payments

Through program year 2025, Zenith Research Inc is reported as receiving $1,825,747 in research payments, across 95 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $499,196 31
2024 Research $508,577 19
2023 Research $31,439 7
2022 Research $75,734 6
2021 Research $120,262 5
2020 Research $280,798 3
2019 Research $309,741 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $880,788 43 payments
  2. Eli Lilly and Company $572,588 9 payments
  3. LEO Pharma AS $121,821 20 payments
  4. Ucb SA $119,540 4 payments
  5. Janssen Research & Development, LLC $79,796 8 payments
  6. Bausch Health US, LLC $39,970 5 payments
  7. Arcutis Biotherapeutics, Inc. $10,360 4 payments
  8. Amgen Inc. $613 1 payment
  9. Galderma Laboratories, L.P. $271 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $532,512 25 payments
  2. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $304,135 2 payments
  3. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $254,278 5 payments
  4. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $168,974 10 payments
  5. TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $147,641 6 payments
  6. A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of Ucb1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) $107,904 1 payment
  7. Tralokinumab Vaccine Response Time $85,406 11 payments
  8. A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis $79,796 8 payments
  9. Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study $39,970 5 payments
  10. Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend $36,415 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record